Manorama Industries Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/vj1d0t4408faijpfkh6p5m7n.pdf

Key Takeaways


Growth & Volume Dynamics

Ekta Soni: "Our products are more value-added product, which is formulated and based on certain specifications and recipes of the confectionery chocolate or cosmetics. So our pricing model, if you say, has been -- remained stable largely, which is in line of our costing model as well."

Capacity Expansion & Capex

Ashish Saraf: "We are steadily advancing our aspiration of becoming the partner of choice for the world's leading food and confectionery and cosmetic companies through strategic investments in research and development, sourcing, manufacturing and market expansion."

Margins & Cost Structure

Ekta Soni: "Margins can see modest quarter-to-quarter movement depending on mix and one-off items. But the underlying lens range is expected to hold broadly stable. At the same time, business is business. Business has risk also."

Subsidiaries & International Build-out

Ekta Soni: "These are deliberate funded investments in the long-term capability. And we see as these entities scale, directionally, their drag on consolidated margins should reduce and over time, turn into a contributor."

Product & Technology Initiatives

Ekta Soni: "Through a technology here in from India, from an ESOS plant, we will convert some of the oil liquid fractions into a hard fraction using some enzymes toward it. So that would convert our liquid fraction into solid fractions that will help convert into a cocoa butter alternative segment, which will be called ECBE, enzymatic cocoa butter equivalent."

Risk & Contingencies

Ekta Soni: "We cannot say that it will not any way not impact us directly. But of course, there is an indirect impact, which is there in terms of freight, logistics or could be other macroeconomic impact could be there. But as a company, we always navigate it and balance it out on what possible ways we could do."

Guidance & Commitments

CommitmentSpecificsTimeline
Debottlenecking completionAdditional 4,500 tons capacity, taking total to ~52,000 tons per annumAround Q3 FY27
Full-year utilization80–85% on expanded 52,000-ton baseFY27
New capex commissioningSolvent fractionation 3, refinery, and Burkina Faso backward integration plantAround Q3 FY28
FY27 capex spendApproximately ₹225–250 croresFY27
Burkina Faso payback~3 years once operationalFrom commissioning
Employee cost run rate₹14–15 crores per quarterGoing forward
Brazil ramp-upGradual quarter-on-quarter ramp-upNext 2–4 quarters
Supplier recoveryFull debit note amount claimed; confident of recoveryWithin a certain time, per SEBI updates
Hedging policy50–60% of net exposure hedgedContinuing policy
Equity dilutionNo further equity dilution plannedNear term

Key Metrics

MetricQ1 FY27
Revenue growth39.5% YoY, crossing ₹400 crore quarterly revenue milestone for the first time
EBITDA₹106 crores
EBITDA margin26.3%, expanded 49 bps YoY
PAT₹79 crores, up 67.6% YoY
PAT margin19.5%, expanded 326 bps YoY
Capacity utilization~80% for Q1; full-year expected at 80% to 85%
CBE and stearin revenue contribution71.4% of revenue; CBE specifically 30%, balance stearin
Export share50% to 60% of revenue, consistent with 55% to 60% in 1Q FY25
Volume growth contribution~85% of the 39% YoY revenue growth was volume-led
Gross margin range45% to 50%, broadly stable
Employee cost run rate₹14 crores to ₹15 crores per quarter expected going forward
Other income₹16 crores, of which ₹13 crores forex gain and ₹3 crores FDR income
Capex guidance FY27₹225 crores to ₹250 crores
Debottlenecking capacity addition4,500 tons expected in FY27, taking capacity from 47,500 to ~52,000 tons per annum
Burkina Faso plant payback~3 years once operational